Parkinson's disease, neurodegenerative disorders, regenerative neurology
My current research focus is on restorative approaches for Parkinson’s disease based upon cell transplant to pseudo-normalize dopamine delivery to the putamen. I participated in the first autologous transplantation of a subject’s own dopamine neuron progenitor cells derived from their own iPS cells (Kwang-Soo Kim PhD, Jeffrey Schweitzer MD PhD) in 2017, and now am developing a focus on other novel first-in-human therapeutic trials. Having served as lead investigator for the Clinical Core of a NYSTEM Consortium award PIs: Lorenz Studer MD and Viviane Tabar MD) entitled “Developing a human ES derived dopamine neuron source for cell therapy in Parkinson’s disease’ (IND January 2021), a clinical trial is now slated for 2021 start-up.
Fellow, American Neurological Association; Fellow, American Academy of Neurology; Daisy and Paul Soros Clinical Scholar in Neurology; Helen M. Sciarra Prize in Neurology
Claire Henchcliffe, M.D., D.Phil. is the Chair and Stanley van den Noort Professor of Neurology, at the University of California, Irvine. She read for her BA in Biochemistry and completed her graduate thesis at the University of Oxford in the UK. She then pursued post-doctoral training in genetics and neuroscience at the University of Cambridge, UK, and the University of California at Berkeley, California. Dr. Henchcliffe received her medical degree from the College of Physicians and Surgeons of Columbia University in New York City. She completed neurology residency and fellowship at the College of Physicians and Surgeons of Columbia University in New York City, prior to joining Weill Cornell Medical College, New York City in 2003. At Weill Cornell Medical College she developed a clinical and research program in movement disorders with a focus on clinical trials including stem cell-based therapeutics, eventually serving as Professor of Neurology and Neuroscience, and Vice Chair for Clinical Research. She served as the Weill Cornell site Principal Investigator for the NIH-funded NeuroNEXT clinical trial network and as Medical Director of the Trial Innovation Unit, for the Weill Cornell Clinical and Translational Science Center to the national NCATS-supported Trial Innovation Network. She left in 2020 to take up her position at UCI. Her current research focuses on developing new treatments for Parkinson’s disease, and she has a specific interest in the potential for data-driven personalized approaches to care, including gene- and cell-based therapies. She has been an investigator and on the steering committees for multiple clinical trials in Parkinson’s disease.
55. Parmar, M., Grealish, S. and Henchcliffe, C. (2020) The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. 21:103-115
56. Barone, D.A., Fei Wang, F., Ravdin, L., Vo, M., Lee, A., Sarva, H., Hellmers, N., Krieger, A.C., Henchcliffe, C. (2020) Comorbid Neuropsychiatric and Autonomic Features in REM Sleep Behavior Disorder. Clin Parkinsonism Rel Disord
57. Waninger, S., Berka, C., Stevanovic Karic, M., Korszen, S., Mozley, P.D., Henchcliffe, C., Kang, Y., Hesterman, J., Tomer Mangoubi, T., and Verma, A. (2020) Neurophysiological Biomarkers of Parkinson’s Disease. J Parkinson Dis. 10(2):471-48
58. Schweitzer, J.S., Song, B., Herrington, T., Park, T.-Y., Lee, N., Ko, S., Jeon, J., Cha, Y., Kim, K., Li, Q., Henchcliffe, C., Kaplitt, M., Neff, C., Rapalino, O., Seo, H., Lee, I.-H., Kim, J., Kim, T., Petsko, G., Ritz, J., Cohen, B., Kong, S.W., Leblanc, P., Carter, B., Kim, K.-S. (2020) Personalized iPSC-derived Dopamine Progenitor Cells for Parkinson’s Disease. N Engl J Med 382: 1926-1932
60. Henchcliffe, C., and Sarva, H. (2020) Restoring Function to Dopaminergic Neurons: Progress in the Development of Cell-Based Therapies for Parkinson's Disease. CNS Drugs. 34(6): 559-577. https://doi.org/10.1007/s40263-020-00727-3
61. Gilvary, C., Elkhader, J., Madhukar, N., Henchcliffe, C., Marcus D. Goncalves, M.D., and Elemento, O. (2020) A computational approach to repurpose approved and investigational small molecules. PLOS Comput Biol 16(8) e1008098
62. Ivanidze, J., Skafida, M., Pandya, S., Patel, D., Osborne, J. R., Raj, A., Gupta, A., Henchcliffe, C. and Dyke, J. P. (2020) Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease. Frontiers in Neuroscience 14:528809. http://journal.frontiersin.org/article/10.3389/fnins.2020.528809/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Neuroscience&id=528809
63. Herrington, T.M., Schweitzer, J., Henchcliffe, C., Carter, R.S., Kim, K.-S. (2020) Towards a Personalized Approach to Parkinson’s Cell Therapy. Mov Disord 35(11): 2119-2120
64. Lee, A., Hellmers, N., Patel, D., Vo, M., Wang, F., Popa, P., Campbell, C., Henchcliffe, C., and Sarva, H. Can Google Glass™ Technology Improve Freezing of Gait in Parkinsonism? A Pilot Study (Disability and Rehabilitation: Assistive Technology, Nov 20:1-11. https://doi.org/10.1080/17483107.2020.1849433 2020.1849433 (online ahead of print) https://doi.org/10.1080/17483107.2021.1900934
65. Piao, J., Susan Zabierowski, S., Dubose, B., Hill, E.J., Navare, M., Claros, N., Siera Rosen, S., Ramnarine, K., Horn, C., Fredrisckson, C., Wong, K., Safford, B., Kriks, S., ElMaarouf, R, Rutishauser, U, Henchcliffe, C., Wang, Y., Riviere, I., Mann, S., Bermudez, V., Irion, S., Studer, L., Tomishima, M., and Tabar, V. (2021) Preclinical Efficacy and Safety of a GMP Grade Human Embryonic Stem Cell-Derived Midbrain Dopamine Progenitor Product, MSK-DA01. Cell Stem Cell 28(2): 217-229.
American Academy of Neurology
American Neurological Association
International Parkinson and Movement Disorders Society (MDS)
International Society for Stem Cell Research (ISSCR)
American Society for Gene and Cell Therapy (ASGCT)